Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of CRPS
Aachen / Pisa (ots) - Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need - Neridronic acid is the first investigational medicine to receive Breakthrough Therapy ...
mehr